LianBio announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from LianBio to pursue other opportunities. In connection with Dr. Wang?s departure, effective December 16, 2023, the Board appointed Adam Stone, member of the Board, as Interim Chief Executive Officer of the Company, until his successor is appointed or his earlier death, resignation or removal. Mr. Stone (44) has served as a member of Board since October 2019.

Since July 2021 and February 2021, respectively, Mr. Stone has served as the Chief Executive Officer of ARYA Sciences Acquisition Corp. V and ARYA Sciences Acquisition Corp. IV, respectively, and as a member of their boards of directors.

Mr. Stone has also served as a member of the boards of directors of Solid Biosciences since November 2015 and Immatics since July 2020. Mr. Stone also serves on the board of directors of Xontogeny LLC. Mr. Stone previously served as the chief executive officer and a member of the board of directors of ARYA Sciences Acquisitions Corps I, II, and III.

Mr. Stone joined Perceptive, a life sciences focused investing firm and affiliate of the Company, in 2006 and has served as Chief Investment Officer since 2012 and is a member of the internal investment committees of Perceptive?s credit opportunities and venture funds. Mr. Stone previously served as a Senior Analyst at Ursus Capital from 2001 to 2006, where he focused on biotechnology and specialty pharmaceuticals. Mr. Stone has also served as a member of the boards of directors of Solid Biosciences since November 2015 and Immatics since July 2020.

Mr. Stone earned a bachelor?s degree in molecular biology from Princeton University.